Aprea Therapeutics 3Q 2026: Revenue $0 Net loss $4.8M, EPS $(0.09) — 10-Q Summary
Aprea Therapeutics reported no revenue and a net loss of $4.8M for Q3 2026, compared to $1.8K revenue and a $3M loss a year earlier. Diluted EPS was $(0.09). The company reported clinical trial updates for APR-1051 and ATRN-119, and plans to expand APR-1051 enrollment and target lead identification for APR-1602 in Q2 2027.
How this was made
The 30-second read
Why it matters
The earnings miss and zero revenue suggest short‑term weakness, but pipeline progress may offer long‑term upside.
Market read
The report is a primary earnings disclosure for a micro‑cap biotech, likely prompting a sell‑off.
What to watch
Potential future grant funding or partnership announcements could mitigate cash‑burn concerns.
Background
Aprea Therapeutics filed its Q3 2026 10‑Q, showing no revenue and a widened net loss, with updates on its Phase 1 trial and pipeline plans.
Ticker impact
Aprea Therapeutics reported Q3 2026 revenue of $0 and a net loss of $4.8M, the first disclosure of these results.
likely downward pressure as investors price in the loss and lack of revenue
Quarterly earnings with a larger loss than the prior year and no revenue typically trigger sell‑offs in micro‑cap biotech stocks.
Market effects
Highlights ongoing funding challenges for early‑stage biotech firms reliant on grant money.
Limited to US biotech micro‑caps; no broader regional effect.
Minimal global impact; primarily relevant to investors in small‑cap biotech.
Counterpoint
If the upcoming trial enrollments succeed, the stock could rebound on future pipeline upside.
Key entities
- companyAprea Therapeutics
US‑listed biotech (ticker APRE) reporting Q3 2026 results.
